[The effectiveness and safety of sparfloxacine in combined therapy for tuberculosis].
The effectiveness and safety of the difluoroquinolone sparflo (sparfloxacine) used in combined therapy for drug-sensitive and drug-resistant pulmonary tuberculosis were studied. Clinical trials were carried out in 60 patients with severe pulmonary tuberculosis. The more effective combinations of sparfo and other antituberculous drugs were determined. Data on the satisfactory tolerability of sparfo used in various combinations of first- and second-line agents are presented.
G B
GB
Sokolova
T Ia
TIa
Khaĭmenova
S E
SE
Borisov
Ia V
IaV
Lazareva
I V
IV
Bogadel'nikova
M G
MG
Biron
G N
GN
Mozhokina
A A
AA
Tsibanev
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology
D000995:Antitubercular Agents; D024841:Fluoroquinolones; C061363:sparfloxacin